Therapies for heart failure are palliative and aimed primarily at delaying pathological cardiac remodeling and progression to advanced disease. LoneStar Heart Inc. is developing a trio of technologies that it believes have the potential to restore the heart's structure and function, reversing disease progression.

President and COO Frank Ahmann said LoneStar's programs target patients with New York Heart Association (NYHA) Class II-III heart failure because "these patients are not optimally treated with pharmaceuticals and are not yet candidates for more invasive and expensive options such as a heart transplant, implantation of a left-ventricular assist device or cardiac resynchronization therapy."